Crunch Time for the Global Harmonization Task Force
This article was originally published in RAJ Devices
Wind down, carry on much as before or be completely reinvented. These were three potential scenarios for the Global Harmonization Task Force that senior medical device regulators and industry executives from around the world were asked to consider at the plenary session of the 12th GHTF conference in Toronto on 12-14 May.
You may also be interested in...
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.